UPMC Enterprises, the medical technology investment arm of UPMC, has purchased interest in RxAnte, a company that uses analytics to predict how patients will adhere to the medications they’re prescribed.
Read more on Pittsburgh Business Times.
Pittsburgh Business Times: UPMC Enterprises invests in prescription analytics company RxAnte
Related Resources
More Resources
12.11.18
Tools Every MAPD Plan Needs to Succeed with Part D Stars Programs
Blog Post
If you’re leading a Medicare Advantage Part D (MAPD) plan, we know you have a lot on your mind right now. To help you make the most of your medication adherence strategy, we’ve done a few things recently that you ought to check out.
12.04.18
CMS Proposed Rules Impact Medicare Advantage Part D Plans
Blog Post
Keeping up with rule and policy changes from the CMS is just part of life for MAPD plans. Recently, however, two in particular are signaling a shift to in the industry: CMS-4180-P and CMS-4185-P. Should these rules become final, MAPD plans and their beneficiaries will notice substantial changes. Here’s what health plan leadership needs to know.
11.28.18
Case Study: Activating Provider Networks to Improve Medication Adherence
Case Study
RxAnte's RxEffect workflow solution has helped MAPD plans increase administrative efficiency, scale interventions, and ultimately drive adherence improvement among their member populations. See how one large national MAPD plan drives adherence using RxEffect.